Evista in Switzerland: prescription, pharmacy and pricing
Evista (Raloxifene) is available in Switzerland under the regulatory framework of Swissmedic (Swiss Agency for Therapeutic Products). This page summarises how the medication is prescribed and dispensed locally, what insurance or the public system cover, and which options exist for legally and safely accessing Evista 60mg.
- Regulator
- Swissmedic (Swiss Agency for Therapeutic Products)
- Currency
- CHF
- Active ingredients
- Raloxifene
- Available dosages
- 60mg
Prescription status in Switzerland
Switzerland classifies medicines into categories A and B (prescription-only), C (sold under pharmacist supervision), D (over-the-counter at pharmacies and Drogerien) and E (general retail). Health insurance (Krankenversicherung) covers most prescription costs subject to a deductible (Franchise) and co-payment. Evista contains the active ingredient Raloxifene, in the Hormones and Birth Control class, and its classification in Switzerland follows the standard rules of Swissmedic (Swiss Agency for Therapeutic Products).
Pharmacy dispensing
Swiss Apotheken/pharmacies are densely distributed with strict licensing; pharmacist counselling is integral to dispensing. Drogerien (drugstores) are unique to the Swiss system and sell category D and E medications without a pharmacist on staff. The pharmacist is the most reliable local source of information on stock, authorised substitutions (generic vs brand) and specific precautions for Evista at the available strengths (60mg).
Online and tele-prescribing access
Swiss online prescription dispensing is regulated by cantonal law, with Swissmedic-licensed services offering tele-prescribing. Cross-border importation for personal use is restricted to small quantities and excludes some controlled substances. Buying Evista from unauthorised sellers or without local verification exposes the user to counterfeit medication and unmonitored use of Raloxifene.
When Evista is prescribed
Evista is approved for prevention and treatment of postmenopausal osteoporosis and for reduction of invasive breast cancer risk in postmenopausal women at increased risk.
Pricing and availability in CHF
Retail pricing in Switzerland depends on the strength (60mg), whether the original brand or an authorised generic is dispensed, and insurance or public-system coverage. The difference between brand and generic is usually the most meaningful economic lever for ongoing use. Comparing prices at two or more locally authorised pharmacies before first refill is recommended.
Frequently asked questions
Do I need a prescription for Evista in Switzerland? ▾
Switzerland classifies medicines into categories A and B (prescription-only), C (sold under pharmacist supervision), D (over-the-counter at pharmacies and Drogerien) and E (general retail). Health insurance (Krankenversicherung) covers most prescription costs subject to a deductible (Franchise) and co-payment. In practice, Evista follows the status of its active ingredient Raloxifene in the regulatory system of Swissmedic (Swiss Agency for Therapeutic Products).
Is generic Evista available in Switzerland? ▾
Authorised generics of Raloxifene are typically available in Switzerland at a lower cost than branded Evista, with bioequivalence required by Swissmedic (Swiss Agency for Therapeutic Products). Substitution is handled by the pharmacist under local equivalence rules.
How much does Evista cost in CHF? ▾
Prices in CHF vary by pharmacy and by strength (60mg). Authorised generics of Raloxifene are usually substantially cheaper than the brand and are the typical economic reference point for ongoing use in Switzerland.
Evista in other countries
- the United StatesFDA (Food and Drug Administration)
- the United KingdomMHRA (Medicines and Healthcare products Regulatory Agency)
- SpainAEMPS (Agencia Española de Medicamentos y Productos Sanitarios)
- MexicoCOFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios)
- ArgentinaANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica)
- GermanyBfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)
- FranceANSM (Agence nationale de sécurité du médicament et des produits de santé)
- ItalyAIFA (Agenzia Italiana del Farmaco)
- BrazilANVISA (Agência Nacional de Vigilância Sanitária)
- CanadaHealth Canada
- South KoreaMFDS (Ministry of Food and Drug Safety)
- JapanPMDA (Pharmaceuticals and Medical Devices Agency)
- AustriaBASG (Federal Office for Safety in Health Care)
- AustraliaTGA (Therapeutic Goods Administration)
- ColombiaInvima (National Food and Drug Surveillance Institute)
- ChileISP (Instituto de Salud Pública de Chile, Public Health Institute)
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.